bezlotoxumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B…
Das Darmbakterium Clostridioides difficile ist eine der häufigsten Ursachen nosokomialer Diarrhöen. Die C.-difficile-Infektion…
Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis…
Abstract Background Recurrent Clostridioides difficile infection (CDI) remains a public health burden, affecting as many as 35…
ABSTRACT Introduction: Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of…
Abstract Background CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that…
n engl j med 376;16 nejm.org April 20, 2017 1596 2. Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention…
Question In patients with Clostridium difficile infection (CDI), does adding bezlotoxumab, with or without actoxumab, to standard…
Background . Treatment guidelines recommend stopping CAs in patients with Clostridium dif fi cile infection (CDI), but this is not…